Literature DB >> 21805237

The proprotein convertases, 20 years later.

Nabil G Seidah1.   

Abstract

The proprotein convertases (PCs) are secretory mammalian serine proteinases related to bacterial subtilisin-like enzymes. The family of PCs comprises nine members, PC1/3, PC2, furin, PC4, PC5/6, PACE4, PC7, SKI-1/S1P, and PCSK9 (Fig. 3.1). While the first seven PCs cleave after single or paired basic residues, the last two cleave at non-basic residues and the last one PCSK9 only cleaves one substrate, itself, for its activation. The targets and substrates of these convertases are very varied covering many aspects of cellular biology and communication. While it took more than 22 years to begin to identify the first member in 1989-1990, in less than 14 years they were all characterized. So where are we 20 years later in 2011? We have now reached a level of maturity needed to begin to unravel the mechanisms behind the complex physiological functions of these PCs both in health and disease states. We are still far away from comprehensively understanding the various ramifications of their roles and to identify their physiological substrates unequivocally. How do these enzymes function in vivo? Are there other partners to be identified that would modulate their activity and/or cellular localization? Would non-toxic inhibitors/silencers of some PCs provide alternative therapies to control some pathologies and improve human health? Are there human SNPs or mutations in these PCs that correlate with disease, and can these help define the finesses of their functions and/or cellular sorting? The more we know about a given field, the more questions will arise, until we are convinced that we have cornered the important angles. And yet the future may well reserve for us many surprises that may allow new leaps in our understanding of the fascinating biology of these phylogenetically ancient eukaryotic proteases (Fig. 3.2) implicated in health and disease, which traffic through the cells via multiple sorting pathways (Fig. 3.3).

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21805237     DOI: 10.1007/978-1-61779-204-5_3

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  64 in total

1.  A genome-wide expression quantitative trait loci analysis of proprotein convertase subtilisin/kexin enzymes identifies a novel regulatory gene variant for FURIN expression and blood pressure.

Authors:  Hannu Turpeinen; Ilkka Seppälä; Leo-Pekka Lyytikäinen; Emma Raitoharju; Nina Hutri-Kähönen; Mari Levula; Niku Oksala; Melanie Waldenberger; Norman Klopp; Thomas Illig; Nina Mononen; Reijo Laaksonen; Olli Raitakari; Mika Kähönen; Terho Lehtimäki; Marko Pesu
Journal:  Hum Genet       Date:  2015-03-27       Impact factor: 4.132

2.  Identification of potent and compartment-selective small molecule furin inhibitors using cell-based assays.

Authors:  Bruno Ramos-Molina; Adam N Lick; Elias H Blanco; J Alejandro Posada-Salgado; Karina Martinez-Mayorga; Alan T Johnson; Guan-Sheng Jiao; Iris Lindberg
Journal:  Biochem Pharmacol       Date:  2015-05-21       Impact factor: 5.858

3.  Mexneurin is a novel precursor of peptides in the central nervous system of rodents.

Authors:  Maura E Matus-Ortega; Philippe Leff Gelman; Juan C Calva-Nieves; Anabel Flores-Zamora; Alberto Salazar-Juárez; Carlos-Alejandro Torner-Aguilar; Gerardo Gamba; Paola De Los Heros; Bonnie Peng; John E Pintar; Heinrich S Gompf; Charles N Allen; Benito Antón-Palma
Journal:  FEBS Lett       Date:  2017-06-01       Impact factor: 4.124

4.  The mechanism by which a propeptide-encoded pH sensor regulates spatiotemporal activation of furin.

Authors:  Danielle M Williamson; Johannes Elferich; Parvathy Ramakrishnan; Gary Thomas; Ujwal Shinde
Journal:  J Biol Chem       Date:  2013-05-07       Impact factor: 5.157

5.  Propeptides are sufficient to regulate organelle-specific pH-dependent activation of furin and proprotein convertase 1/3.

Authors:  Stephanie L Dillon; Danielle M Williamson; Johannes Elferich; David Radler; Rajendra Joshi; Gary Thomas; Ujwal Shinde
Journal:  J Mol Biol       Date:  2012-06-25       Impact factor: 5.469

6.  Regulation of HIF-1 alpha by the proprotein convertases furin and PC7 in human squamous carcinoma cells.

Authors:  Jian Fu; Jirong Zhang; Yulan Gong; Courtney Lyons Testa; Andres J Klein-Szanto
Journal:  Mol Carcinog       Date:  2014-01-16       Impact factor: 4.784

7.  Precision mapping of the human O-GalNAc glycoproteome through SimpleCell technology.

Authors:  Catharina Steentoft; Sergey Y Vakhrushev; Hiren J Joshi; Yun Kong; Malene B Vester-Christensen; Katrine T-B G Schjoldager; Kirstine Lavrsen; Sally Dabelsteen; Nis B Pedersen; Lara Marcos-Silva; Ramneek Gupta; Eric Paul Bennett; Ulla Mandel; Søren Brunak; Hans H Wandall; Steven B Levery; Henrik Clausen
Journal:  EMBO J       Date:  2013-04-12       Impact factor: 11.598

8.  Deficiency in prohormone convertase PC1 impairs prohormone processing in Prader-Willi syndrome.

Authors:  Lisa C Burnett; Charles A LeDuc; Carlos R Sulsona; Daniel Paull; Richard Rausch; Sanaa Eddiry; Jayne F Martin Carli; Michael V Morabito; Alicja A Skowronski; Gabriela Hubner; Matthew Zimmer; Liheng Wang; Robert Day; Brynn Levy; Ilene Fennoy; Beatrice Dubern; Christine Poitou; Karine Clement; Merlin G Butler; Michael Rosenbaum; Jean Pierre Salles; Maithe Tauber; Daniel J Driscoll; Dieter Egli; Rudolph L Leibel
Journal:  J Clin Invest       Date:  2016-12-12       Impact factor: 14.808

9.  Enhanced UV-induced skin carcinogenesis in transgenic mice overexpressing proprotein convertases.

Authors:  Jian Fu; Daniel E Bassi; Jirong Zhang; Tianyu Li; Kathy Q Cai; Courtney Lyons Testa; Emmanuelle Nicolas; Andres J Klein-Szanto
Journal:  Neoplasia       Date:  2013-02       Impact factor: 5.715

10.  Hexa-D-arginine treatment increases 7B2•PC2 activity in hyp-mouse osteoblasts and rescues the HYP phenotype.

Authors:  Baozhi Yuan; Jian Q Feng; Stephen Bowman; Ying Liu; Robert D Blank; Iris Lindberg; Marc K Drezner
Journal:  J Bone Miner Res       Date:  2013-01       Impact factor: 6.741

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.